ReviewGynecologic oncology2016

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.